Actively Recruiting
CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors
Led by Second Affiliated Hospital of Guangzhou Medical University · Updated on 2024-06-25
200
Participants Needed
1
Research Sites
730 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is an open, exploratory clinical study to evaluate the safety and preliminary efficacy of Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells in patients with Claudin6, GPC3, Mesothelin, or AXL-positive advanced solid tumors (ovarian cancer and others)
CONDITIONS
Official Title
CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with advanced ovarian cancer or other cancers expressing Claudin6
- Life expectancy greater than 12 weeks
- Adequate heart, lung, liver, and kidney function
- Availability of autologous transduced NK cells with at least 20% expression of Claudin6, GPC3, Mesothelin, or AXL-CAR by flow cytometry and at least 20% killing activity against Claudin6-positive targets in cytotoxicity assay
- Informed consent given by patient or guardian with understanding and a copy provided
You will not qualify if you...
- Previous gene therapy
- Tumor size larger than 25 cm
- Severe viral infections such as hepatitis B, hepatitis C, or HIV
- Known HIV positive status
- History of liver or kidney transplantation
- Active bacterial, viral, or fungal infections
- Other severe diseases deemed unsuitable by investigators
- Pregnant or lactating women
- Systemic steroid treatment at or above 0.5 mg prednisone equivalent per kg per day
- Other conditions considered inappropriate by investigators
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Actively Recruiting
Research Team
Z
Zhenfeng Zhang, MD, PHD
CONTACT
B
Bingjia He, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here